We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Analysis

5 Things To Watch As Indivior Attacks DOJ Opioid Indictment

Law360 (April 11, 2019, 10:02 PM EDT) -- Indivior has enlisted Covington & Burling and a former federal prosecutor with 40 years of experience in its bet-the-company battle against a U.S. Department of Justice indictment that echoes long-running antitrust and False Claims Act suits alleging shady opioid sales. Here, Law360 spotlights five things to watch in the multibillion-dollar case.

10-Figure Financial Stakes

The indictment on Tuesday rocked U.K.-based Indivior Inc., formerly known as Reckitt Benckiser Pharmaceuticals Inc., with 28 felony counts involving mail, wire and health care fraud.

The DOJ wants Indivior to forfeit a staggering $3 billion — triple the $1 billion in global revenue that Indivior earned in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS